Thermo Fisher Scientific announced a strategic collaboration with Mirai Bio, a company founded by Flagship Pioneering, to benefit the life sciences and genetic medicines marketplace. This partnership will pair Thermo Fisher's developmental and current Good Manufacturing Practice (cGMP) services, commercial manufacturing capabilities, and global capacity with Mirai's innovative technology platform.
Mirai's platform is designed for optimizing the design, delivery, and development of novel nucleic acid therapeutics through machine intelligence-based high-throughput design and in vivo testing of tissue-targeted delivery vehicles. This collaboration initially leverages the capabilities of Thermo Fisher's facility for RNA and Advanced Formulations.
The agreement also includes a direct investment into Mirai as part of Flagship Pioneering's existing partnership with Thermo Fisher, which aims to jointly develop transformative capabilities for the industry. This strategic move positions Thermo Fisher at the forefront of cutting-edge genetic medicine development and manufacturing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.